{"entity":{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","aka":[],"tldr":"Photys Therapeutics builds two-headed molecules that bring a target protein next to an enzyme that modifies or destroys it. Its first clinical drug is for autoimmune disease; its cancer work, aimed at a mutant form of the p53 protein, is still in the laboratory.","summary":"Photys Therapeutics is a Boston proximity-based therapeutics company with three heterobifunctional platforms: PROTAC degraders, PHICS (phosphorylation-inducing chimeric small molecules that recruit kinases to a target) and tPRIME (targeted proximity-induced modulators of expression). Its lead clinical programme, PHT-776/HPB-143, an oral IRAK4 PROTAC degrader licensed from Polymed in February 2025, entered phase 1 in August 2026 for autoimmune and inflammatory diseases. The oncology programme is preclinical: tPRIME bifunctionals directed at p53 Y220C, with data on p53-Y220C-BET bifunctionals driving cancer cell death presented in February 2025. A PHICS collaboration with Novo Nordisk (December 2024) covers cardiometabolic targets. Photys launched in September 2022 with a 75 million US dollar Series A led by MPM Capital, joined by Omega Funds, Longwood, 8VC, Eli Lilly and others.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.photys.com/"},{"label":"Series A press release","url":"https://www.photys.com/sep-08-2022-75million-series-a-funding-for-precision-phosphorylation"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["protac-degrader"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Oncology is a preclinical part of a mostly immunology and cardiometabolic pipeline. No SEC Form D filings were found under the company name. Founding year not sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.photys.com/","stage":"startup","investors":["mpm-bioimpact","omega-funds","longwood-fund"],"funding":[{"round":"Series A","year":2022,"amountUsd":75000000,"source":"https://www.photys.com/sep-08-2022-75million-series-a-funding-for-precision-phosphorylation","note":"Led by MPM Capital; company founded by Longwood Fund and Amit Choudhary of Brigham and Women's Hospital and the Broad Institute"}]},"route":"/companies/photys-therapeutics/","neighbours":{"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"company":[{"id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/"},{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/"},{"id":"omega-funds","kind":"company","name":"Omega Funds","route":"/companies/omega-funds/"}]}}